Business
Cellectis Reports Financial Results for the First Quarter 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral
About this update from Cellectis S.a.
[{"type":"image","alt":"Cellectis Inc.","displaySize":"","headline":null,"caption":"Cellectis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U3etrkPEbdAWocW4KkNDeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97","width":300,"height":119}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Cellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meeting","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash position of $246 million as of March 31, 20251 provides runway into H2 2027","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":655,"olType":false},{"type":"text","content":"NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.","length":355,"tagName":"p"},{"type":"text","content":"« We are making progress in our wholly-owned clinical studies and in the three programs under our strategic partnership with AstraZeneca. We will continue to focus our efforts and resources on advancing these core programs and are looking forward to the results expected over the next few months » said André Choulika, Ph.D., Chief Executive Officer at Cel...